1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine | 130157-42-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
• 英文别名: 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine；edelfosine；ET 18-OCH3；AP-121；3-Octadecyloxy-2-methoxypropylphosphonocholine；2-[hydroxy-(2-methoxy-3-octadecoxypropoxy)phosphoryl]oxyethyl-trimethylazanium
• CAS: 130157-42-5
• 化学式: C₂₇H₅₉NO₆P
• 分子量: 524.742
• InChiKey: MHFRGQHAERHWKZ-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  35
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine 在 Chiralpak IC 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 R-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine 、 S-1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine
  参考文献：
  名称：

  [EN] S-ENANTIOMER OF A TRI-SUBSTITUTED GLYCEROL COMPOUND
  [FR] ENANTIOMÈRE S D'UN COMPOSÉ GLYCÉROL TRI-SUBSTITUÉ

  摘要：

  本发明涉及三取代甘油化合物的S-对映体。本发明还涉及包含该化合物或其药学上可接受的盐的制药组合物。此外，本发明还涉及将AP-121对映体的混合物分离成S-对映体和R-对映体的方法。

  公开号：

  WO2013156630A1
• 作为产物：
  描述：

  1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphoethanolamine 、 碘甲烷 在 甲醇 、 sodium hydroxide 作用下， 以 氯仿 为溶剂， 反应 2.0h， 生成 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
  参考文献：
  名称：

  Alunni-Bistocchi; Orvietani; Ricci, Il Farmaco, 1990, vol. 45, # 5, p. 499 - 509

  摘要：

  DOI：

文献信息

• POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
  申请人：ModernaTX, Inc.

  公开号：EP3896164A1

  公开（公告）日：2021-10-20

  The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.

  本发明涉及治疗法布里病的mRNA疗法。用于本发明的mRNA在体内给药时，编码人的α-半乳糖苷酶A（GLA）、其同工型、其功能片段和包含GLA的融合蛋白。本发明的mRNA优选封装在脂质纳米颗粒（LNPs）中，以便在给药时有效地传递到受试者的细胞和/或组织中。本发明的mRNA疗法可提高和/或恢复受试者体内不足的GLA表达和/或活性水平。本发明的mRNA疗法可进一步降低与受试者体内GLA活性不足有关的毒性代谢物，即Gb3和溶菌酶Gb3的水平。
• NEUE PHOSPHORVERBINDUNGEN UND DIESE ENTHALTENDE ARZNEIMITTEL
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP0248858B1

  公开（公告）日：1990-02-28
• POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
  申请人：ModernaTX, Inc.

  公开号：EP3458590B9

  公开（公告）日：2021-08-18
• NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF
  申请人：PERRISSOUD Daniel

  公开号：US20070167408A1

  公开（公告）日：2007-07-19

  The present invention provides novel alkyl phospholipid derivatives with reduced cytotoxicity that are useful for treating various diseases and/or pathophysiological conditions in mammals, preferably humans, that are caused by microorganisms, in particular bacteria, fungi, protozoa and/or viruses. Such alkyl phospholipids can be employed as single drugs or in the course of combination therapies and can also be used for the treatment of tumors.
• Means and Methods for the Treatment and Prevention of Allergic Diseases
  申请人：Braxmeier Tobias

  公开号：US20090018105A1

  公开（公告）日：2009-01-15

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma.